Cargando…

Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study

Esaxerenone, a mineralocorticoid receptor blocker (MRB), is a new antihypertensive agent. However, esaxerenone-related data with respect to hypertension with heart failure are limited. We investigated the safety and efficacy of esaxerenone in hypertensive patients with heart failure with reduced eje...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iwahana, Togo, Saito, Yuichi, Okada, Sho, Kato, Hirotoshi, Ono, Ryohei, Kobayashi, Yoshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575262/ https://www.ncbi.nlm.nih.gov/pubmed/34748605 http://dx.doi.org/10.1371/journal.pone.0259485

Ejemplares similares

Literature reviews of stroke with hypereosinophilic syndrome
por: Ono, Ryohei, et al.
Publicado: (2021)

Heart rate response during cardiopulmonary exercise in the denervated heart
por: Ono, Ryohei, et al.
Publicado: (2023)

Winking earlobe sign
por: Ono, Ryohei, et al.
Publicado: (2022)

Double heart after heart transplantation
por: Ono, Ryohei, et al.
Publicado: (2022)

Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Variant NAXOS-Carvajal Syndrome with Rare Additional Features of Systemic Bulla and Brittle Nails: A Case Report and Literature Review
por: Sato, Takanori, et al.
Publicado: (2020)

Novel myocardial markers GADD45G and NDUFS5 identified by RNA-sequencing predicts left ventricular reverse remodeling in advanced non-ischemic heart failure: a retrospective cohort study
por: Iwahana, Togo, et al.
Publicado: (2020)

Association between early intensive care or coronary care unit admission and post-discharge performance of activities of daily living in patients with acute decompensated heart failure
por: Kanda, Masato, et al.
Publicado: (2021)

Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
por: Kurata, Akifumi, et al.
Publicado: (2019)

Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males
por: Toyama, Kaoru, et al.
Publicado: (2021)

Sex Differences in Heart Failure With Preserved Ejection Fraction
por: Sotomi, Yohei, et al.
Publicado: (2021)

Wellens Syndrome
por: Ono, Ryohei, et al.
Publicado: (2022)

Minimal subphenotyping model for acute heart failure with preserved ejection fraction
por: Sotomi, Yohei, et al.
Publicado: (2022)

ODP190 Efficacy of Esaxerenone on Hypertensive Patients with Type 2 Diabetes or Those with Impaired Glucose Tolerance
por: Kuwabara, Saki, et al.
Publicado: (2022)

Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Right ventricular dominant myocarditis requiring cardiac resynchronization therapy‐defibrillator: a case report
por: Sato, Takanori, et al.
Publicado: (2021)

Heart-hand Syndrome
por: Ono, Ryohei, et al.
Publicado: (2020)

Prognostic Implications of Changes in Left Ventricular Ejection Fraction and Pulmonary Hypertension in Patients with Heart Failure with Reduced Ejection Fraction
por: Kim, Hyun-Jin
Publicado: (2019)

Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
por: Ito, Sadayoshi, et al.
Publicado: (2020)

Mode of Death Among Japanese Adults With Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Kitai, Takeshi, et al.
Publicado: (2020)

Heart Failure With Preserved Ejection Fraction vs. Reduced Ejection Fraction　― Mechanisms of Ventilatory Inefficiency During Exercise in Heart Failure ―
por: Tsujinaga, Shingo, et al.
Publicado: (2020)

Pulmonary Hypertension in Patients With Heart Failure With Mid-Range Ejection Fraction
por: Maeder, Micha T., et al.
Publicado: (2021)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Improvement of Left Ventricular Ejection Fraction and Pulmonary Hypertension Are Significant Prognostic Factors in Heart Failure with Reduced Ejection Fraction Patients
por: Kwon, Hee-Jin, et al.
Publicado: (2019)

Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study
por: Uchida, Haruhito A., et al.
Publicado: (2022)

Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study
por: Kario, Kazuomi, et al.
Publicado: (2023)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Association of Antihypertensive Effects of Esaxerenone with the Internal Sodium Balance in Dahl Salt-Sensitive Hypertensive Rats
por: Hattori, Mai, et al.
Publicado: (2022)

Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors
por: Ovchinnikov, Artem, et al.
Publicado: (2022)

Prognostic significance of high-sensitivity cardiac troponin in patients with heart failure with preserved ejection fraction
por: Suzuki, Sho, et al.
Publicado: (2019)

Diagnostic value of expired gas analysis in heart failure with preserved ejection fraction
por: Saito, Yuki, et al.
Publicado: (2023)

Antihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism
por: Fujimoto, Masanori, et al.
Publicado: (2023)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Adiposity and clinical outcomes in East Asian patients with heart failure and preserved ejection fraction
por: Seki, Yuko, et al.
Publicado: (2022)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Predictors and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients With a Left Ventricular Ejection Fraction Above or Below 60%
por: Nakagawa, Akito, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ihlndiilkmk6jgihrpgsutbqpe